Geron Corporation GERN
Geron Corporation (Nasdaq: GERN) is a hematology drug developer. Its lead program, imetelstat (RYTELO) IMpactMF, is in Phase 3 for intermediate-2 or high-risk relapsed/refractory myelofibrosis. Its next catalyst on record is imetelstat IMpactMF: Interim overall survival analysis (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: imetelstat IMpactMF — Interim overall survival analysis (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| imetelstat (RYTELO) IMpactMF | relapsed/refractory myelofibrosis (post-JAK inhibitor) | oligonucleotide-other | Phase 3 |
| imetelstat IMpress (investigator-led) | higher-risk MDS and AML | oligonucleotide-other | Phase 2 |
| imetelstat IMAGINE (investigator-led) | relapsed/refractory AML | oligonucleotide-other | Phase 2 |
| imetelstat IMproveMF | frontline myelofibrosis (combination) | oligonucleotide-other | Phase 1 |
| Next-generation telomerase inhibitors | — | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
- Incyte Corp INCY
- Grifols SA GRFS
- Disc Medicine, Inc. IRON
- Agios Pharmaceuticals, Inc. AGIO
- Nuvectis Pharma, Inc. NVCT
- X4 Pharmaceuticals, Inc XFOR
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.